A tighter archive for life-science signals.
Search once, then narrow by source or topic.
‘The only thing that saves us is data’: Allogeneic CAR-T biotechs fight for relevance as industry moves on
‘The only thing that saves us is data’: Allogeneic CAR-T biotechs fight for relevance as industry moves on
Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario
Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario
Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play
Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play
GE HealthCare debuts tech to help hospitals remotely maintain bedside ECG stations
GE HealthCare debuts tech to help hospitals remotely maintain bedside ECG stations
Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale
Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale
Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill
Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill
Evommune's Dupixent-like phase 2 eczema data drive 75% stock rally
Evommune's Dupixent-like phase 2 eczema data drive 75% stock rally
Merck teams up with British medtech to boost vaginal therapeutics delivery system
Merck teams up with British medtech to boost vaginal therapeutics delivery system
AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data
Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data
Bristol Myers and Evinova pen global development partnership
Bristol Myers and Evinova pen global development partnership
FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned'
FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned'
FDA slaps highest-risk recall notice on J&J Medtech Cerepak detachable coils
FDA slaps highest-risk recall notice on J&J Medtech Cerepak detachable coils
Takeda inks $1.7B AI drug discovery deal with Iambic Therapeutics
Takeda inks $1.7B AI drug discovery deal with Iambic Therapeutics
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'
Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'
CSL signs on to $328M research collab with option for Memo’s immunoglobulin antibody tech
CSL signs on to $328M research collab with option for Memo’s immunoglobulin antibody tech
How AI Is reshaping clinical trials and market access
How AI Is reshaping clinical trials and market access
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page